Cefiderocol: A Novel Siderophore Cephalosporin Defeating Carbapenem-resistant Pathogens

被引：37
作者：
Bonomo, Robert A. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
机构：
[1] Vet Affairs Med Ctr, Med Serv, Louis Stokes Cleveland Dept, 10701 East Blvd, Cleveland, OH 44106 USA
[2] Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA
[3] Case Western Reserve Univ, Dept Pharmacol, Cleveland, OH 44106 USA
[4] Case Western Reserve Univ, Dept Mol Biol & Microbiol, Cleveland, OH 44106 USA
[5] Case Western Reserve Univ, Dept Biochem, Cleveland, OH 44106 USA
[6] Case Western Reserve Univ, Dept Prote & Bioinformat, Cleveland, OH 44106 USA
[7] CWRU Cleveland VAMC Case VA CARES, Cleveland, OH USA
来源：
CLINICAL INFECTIOUS DISEASES | 2019年 / 69卷
关键词：
cefiderocol; cephalosporin; carbapenem-resistant Enterobacteriaceae; nonfermenting gram-negative bacteria; siderophore; GRAM-NEGATIVE PATHOGENS; LACTAMASE INHIBITOR; MULTIDRUG-RESISTANT; BACTERIA;
D O I：
10.1093/cid/ciz823
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Cefiderocol, a novel siderophore cephalosporin in late-stage clinical development, utilizes a "Trojan horse" active transport mechanism to enter bacteria and has proven in vitro activity against carbapenem-resistant gram-negative pathogens, including those with major carbapenem-resistance mechanisms, and stability against all carbapenemases.
引用
收藏
页码：519 / 520
页数：2
相关论文
共 25 条
  • [1] [Anonymous], 2017, ANTIMICROB AGENTS CH
  • [2] Cefiderocol (S-649266), A new siderophore cephalosporin exhibiting potent activities against Pseudomonas aeruginosa and other gram-negative pathogens including multi-drug resistant bacteria: Structure activity relationship
    Aoki, Toshiaki
    Yoshizawa, Hidenori
    Yamawaki, Kenji
    Yokoo, Katsuki
    Sato, Jun
    Hisakawa, Shinya
    Hasegawa, Yasushi
    Kusano, Hiroki
    Sano, Masayuki
    Sugimoto, Hideki
    Nishitani, Yasuhiro
    Sato, Takafumi
    Tsuji, Masakatsu
    Nakamura, Rio
    Nishikawa, Toru
    Yamano, Yoshinori
    [J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2018, 155 : 847 - 868
  • [3] Bassetti Matteo, 2018, Drugs Context, V7, P212527, DOI 10.7573/dic.212527
  • [4] Carbapenemase-Producing Organisms: A Global Scourge
    Bonomo, Robert A.
    Burd, Eileen M.
    Conly, John
    Limbago, Brandi M.
    Poirel, Laurent
    Segre, Julie A.
    Westblade, Lars F.
    [J]. CLINICAL INFECTIOUS DISEASES, 2018, 66 (08) : 1290 - 1297
  • [5] 10 x '20 Progress-Development of New Drugs Active Against Gram-Negative Bacilli: An Update From the Infectious Diseases Society of America
    Boucher, Helen W.
    Talbot, George H.
    Benjamin, Daniel K., Jr.
    Bradley, John
    Guidos, Robert J.
    Jones, Ronald N.
    Murray, Barbara E.
    Bonomo, Robert A.
    Gilbert, David
    [J]. CLINICAL INFECTIOUS DISEASES, 2013, 56 (12) : 1685 - 1694
  • [6] Cai B., 2017, Open Forum Infect. Dis, V4, DOI [DOI 10.1093/OFID/OFX176, 10.1093/ofid/ofx176]
  • [7] Doi Y., 2019, CLIN INFECT DIS S7, V69, P565
  • [8] Pathogen-focused Clinical Development to Address Unmet Medical Need: Cefiderocol Targeting Carbapenem Resistance
    Echols, Roger
    Ariyasu, Mari
    Den Nagata, Tsutae
    [J]. CLINICAL INFECTIOUS DISEASES, 2019, 69 : 559 - 564
  • [9] Therapies for multidrug resistant and extensively drug-resistant non-fermenting gram-negative bacteria causing nosocomial infections: a perilous journey toward "molecularly targeted' therapy
    El Chakhtoura, Nadim G.
    Saade, Elie
    Iovleva, Alina
    Yasmin, Mohamad
    Wilson, Brigid
    Perez, Federico
    Bonomo, Robert A.
    [J]. EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2018, 16 (02) : 89 - 110
  • [10] European Centre for Disease Prevention and Control (EARS), 2017, SURV ANT RES EUR ANN
123